Skip to Main Content

Sarah Weiss, MD

Assistant Professor Adjunct; Assistant Professor (Medical Oncology)

Contact Information

Sarah Weiss, MD

Research Summary

Some of Dr. Weiss' ongoing research includes the development of new immunotherapeutic strategies for patients with melanoma and renal cell carcinoma whose disease has progressed on standard immunotherapy.

Extensive Research Description

Dr. Weiss joined the Melanoma and Renal Cell Carcinoma Disease Aligned Research Team at Yale in August 2016 and has a growing clinical practice. Her primary research interests are to develop innovative clinical trials for the management of advanced melanoma, and to identify and integrate prognostic and predictive biomarkers into clinical practice. She is currently the site Principal Investigator on several clinical trials including a study of Apexigen’s CD40 agonist in combination with nivolumab in patients with melanoma who are resistant to PD-1 immune checkpoint inhibitors. This has led to an investigator-initiated clinical trial protocol that Dr. Weiss wrote based off of preclinical work conducted in the Kaech and Bosenberg laboratories here at Yale, aimed at overcoming resistance to PD-1/PD-L1 agents by targeting both the innate and adaptive immune systems with a triple combination of a CD40 agonist, CSF1R inhibitor, and PD-1 inhibitor.


Research Interests

Immunotherapy; Melanoma

Public Health Interests


Selected Publications